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OBJECTIVE: To compare ticagrelor and prasugrel with clopidogrel for recurrent
fatal and non-fatal myocardial infarction (reMI) in real-life conditions.
METHODS: Case-referent study using the Pharmacoepidemiological General
Research eXtension (PGRx)-acute coronary syndrome (ACS) registry. Cases were
patients with reMI from a cohort with index ACS or external to the cohort (same
sites). Referents from the cohort, without recurrent event, were matched on index
ACS type and date, age and sex with reMI cases. Multivariate conditional logistic
regression assessed the OR (95% CI) for reMI associated with ticagrelor and
prasugrel vs clopidogrel, adjusted for aspirin use and cardiovascular risk factors.
RESULTS: 1047 cases and 2234 matched referents were included. Compared with
clopidogrel, ticagrelor and prasugrel were associated with respective ORs of 0.65
(95% CI 0.52 to 0.81) and 0.71 (95% CI 0.53 to 0.96) for reMI occurrence. ORs for
ticagrelor and prasugrel vs clopidogrel were: 0.50 (95% CI 0.38 to 0.67) and 0.66
(95% CI 0.45 to 0.95), 0.39 (95% CI 0.24 to 0.62) and 0.44 (95% CI 0.26 to 0.75),
0.63 (95% CI 0.43 to 0.92) and 1.20 (95% CI 0.69 to 2.07), 1.11 (95% CI 0.72 to
1.72) and 0.82 (95% CI 0.44 to 1.54) when index ACS was a first MI, a first ST-
elevated MI (STEMI), a first non-STEMI and a recurrent ACS, respectively, and
0.63 (95% CI 0.45 to 0.87) and 0.77 (95% CI 0.41 to 1.45) for patients aged ≥70
 years.
CONCLUSIONS: This real-world study showed a significant reduction of reMI with
new antiplatelets compared with clopidogrel, ticagrelor being associated with a
greater decrease of risk notably for first, either STEMI or non-STEMI. The larger
magnitude of effect may be attributed to potential residual confounding or higher
effectiveness compared with efficacy reported in trials (EMA Post Authorisation
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